MIN-117
Clinical data | |
---|---|
Other names | WF-516 |
Identifiers | |
| |
JSmol) | |
| |
|
MIN-117 (known formerly as WF-516) is an investigational
affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.[7]
See also
References
- PMID 22880045.
- ^ "Minerva Neuroscience". Retrieved 2015-05-19.
- ^ a b Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved 2015-05-19.
- ^ a b c Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19.
- ^ "Company Profile for Minerva Neurosciences Inc". Reuters. Archived from the original on 2015-05-20. Retrieved 2015-05-19.
- ^ a b Dion D (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.
- ^ "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder". BioSpace. Retrieved 2020-07-28.